Karl Matuszewski joins First DataBank
SOUTH SAN FRANCISCO, Calif. — Drug database provider First DataBank has appointed former Gold Standard/Elsevier editor-in-chief Karl Matuszewski as VP clinical and editorial knowledge-base services, the company said Tuesday.
In the new role, Matuszewski will guide editorial policy development for the creation and maintenance of First DataBank’s knowledge-base services and disease decision support products, including National Drug Data File Plus, OrderView Med Knowledge Base and related clinical modules.
“We are pleased to have Karl join the leadership at First DataBank,” First DataBank president and CEO Greg Dorn said. “His deep clinical expertise and knowledge of drug informatics will be of great value to First DataBank and will ensure that the clinical content we publish will continue to evolve to support our vision for innovative client solutions.”
IMS Health expands with SDI Health acquisition
NEW YORK — Healthcare market research firm IMS Health will buy privately held market research firm SDI Health, IMS said.
Terms of the transaction were not disclosed, but the deal would bring together two of the leading healthcare analytics companies. In terms of drug industry analytics, IMS focuses on drug sales and dispensed prescriptions, while SDI provides data on prescriptions written by physicians and other prescribers.
IMS, which has existed for more than 55 years and operates in more than 100 countries, said the acquisition would enable more robust patient and specialty analytics while allowing it to reach out to a broader set of stakeholders.
Transcept seeks regulatory approval for Intermezzo
POINT RICHMOND, Calif. — Transcept Pharmaceuticals has resubmitted its regulatory application for a drug to treat insomnia to the Food and Drug Administration, following a previous denial of approval by the agency, the drug maker said Tuesday.
Transcept sent in its application for Intermezzo (zolpidem tartrate), a pill placed under the tongue for treating patients who awake in the middle of the night and have difficulty falling asleep again.
In October 2009, the company received a complete response letter from the FDA, and the resubmission contains additional clinical study data.